BetterLife Pharma Inc., a Vancouver-based emerging biopharmaceutical company, has announced its participation in the YAFO Capital Access Asia 2025 Partnering Forum, scheduled during the prestigious JPM Week in San Francisco, California. This event, set for January 11, 2026, is designed to bridge innovative life science firms from North America with leading investors, pharmaceutical partners, and strategic advisors from Asia, emphasizing cross-continental partnerships in the biopharma sector..

总部位于温哥华的新兴生物制药公司BetterLife Pharma Inc.宣布将参加预定于加利福尼亚州旧金山举行的享有盛誉的JPM周期间的YAFO Capital Access Asia 2025合作伙伴论坛。该活动定于2026年1月11日举行，旨在连接北美的创新生命科学公司与来自亚洲的领先投资者、制药合作伙伴和战略顾问，重点放在生物制药领域的跨洲合作上。

The forum provides a critical platform for companies like BetterLife to showcase their pipelines and engage in high-level discussions on investment and collaboration opportunities. BetterLife's involvement underscores its strategic push into Asian markets, where capital and expertise in neurological disorder treatments are increasingly concentrated.

该论坛为像BetterLife这样的公司提供了一个关键平台，以展示其研发管线，并就投资和合作机会进行高层讨论。BetterLife的参与突显了其进军亚洲市场的战略，因为在这些市场中，神经系统疾病治疗领域的资本和专业知识正日益集中。

Dr. Ahmad Doroudian, Chief Executive Officer of BetterLife, will lead the company's representation, making himself available for one-on-one meetings with potential investors and partners interested in the firm's development strategy..

贝特莱夫公司的首席执行官艾哈迈德·多鲁迪安博士将带领公司进行业务洽谈，并与对公司发展战略感兴趣的潜在投资者和合作伙伴进行一对一的会面。

Central to BetterLife's presentation is BETR-001, its proprietary patented stereoisomer of 2-bromo-LSD, a non-hallucinogenic derivative of LSD. This neuroplastogen is under development for treating neurological disorders including traumatic brain injury (TBI), post-traumatic stress disorder (PTSD), and cluster headaches.

BetterLife 公司展示的核心是 BETR-001，这是其专有的 2-溴-LSD 的专利立体异构体，一种非致幻性的 LSD 衍生物。这种神经塑性因子正在开发用于治疗包括创伤性脑损伤 (TBI)、创伤后应激障碍 (PTSD) 和丛集性头痛在内的神经系统疾病。

Preclinical and IND-enabling studies are underway, highlighting BETR-001's potential as a breakthrough therapy due to its non-hallucinogenic profile, safety in human trials, and self-administration capability since it is unregulated and non-controlled..

临床前和IND支持性研究正在进行中，突显了BETR-001由于其非致幻特性、在人体试验中的安全性以及因不受监管和非管制而具备的自我管理能力，有潜力成为突破性疗法。

Prior clinical data on 2-bromo-LSD forms have demonstrated safety, tolerability, and efficacy in reducing cluster headache frequency, as evidenced by a small study published in Cephalgia in 2010. BetterLife's synthesis patent removes significant regulatory hurdles, while its pending composition and method-of-use patent extends protection until approximately 2042, covering various neurological indications.

先前关于2-溴-LSD形式的临床数据已证明其在减少丛集性头痛频率方面的安全性、耐受性和有效性，这在2010年发表于《Cephalgia》的一项小型研究中得到了证实。BetterLife的合成专利去除了重大的监管障碍，而其待批的成分和使用方法专利将保护期限延长至大约2042年，涵盖各种神经学适应症。

This intellectual property portfolio positions BETR-001 as a commercially viable asset with broad therapeutic potential..

该知识产权组合使 BETR-001 成为具有广泛治疗潜力的商业可行资产。

Beyond the YAFO forum, Dr. Doroudian will attend complementary events to maximize networking: the H7 Life Science Investment Forum & China Night Reception on January 12, the WuXi Global Forum 2026 on January 13, and the DARPA and Ferocity Capital Biodefence Summit also on January 13. These gatherings further amplify opportunities for strategic alliances, particularly with Chinese and broader Asian stakeholders prominent in biopharma innovation..

除了YAFO论坛，Doroudian博士还将参加其他配套活动以最大化人脉拓展：1月12日的H7生命科学投资论坛和中国之夜招待会、1月13日的药明康德全球论坛2026，以及同一天举行的DARPA和Ferocity Capital生物防御峰会。这些聚会进一步扩大了战略联盟的机会，特别是与在生物医药创新领域占据重要地位的中国及更广泛的亚洲利益相关者之间的合作机会。

BetterLife Pharma's broader portfolio includes a drug candidate for viral infections, for which the company is exploring strategic alternatives. This diversified approach aligns with industry trends toward partnerships that accelerate development and commercialization, especially in Asia where rapid clinical data generation and expertise in oncology and other high-value areas are dominant..

BetterLife Pharma更广泛的产品组合包括一种用于病毒感染的候选药物，公司正在为此探索战略替代方案。这种多元化的方法符合行业趋势，即通过合作来加速开发和商业化，尤其是在亚洲，快速生成临床数据以及在肿瘤学和其他高价值领域的专业技能占据主导地位。

The company's participation reflects a larger movement in biopharma toward Asia-focused B2B engagements. As North American firms face funding pressures, events like YAFO facilitate access to Asian capital, which saw deal values surge to $92.2 billion through November 2025, nearly double the previous year.

公司参与反映了生物制药行业向以亚洲为中心的B2B合作的更大趋势。随着北美公司面临资金压力，像YAFO这样的活动促进了获取亚洲资本的机会，截至2025年11月，交易额飙升至922亿美元，几乎是前一年的两倍。

BetterLife's focus on neuroplastogens taps into unmet needs in neurology, where Asian markets offer both investment and patient populations for trials..

BetterLife专注于神经塑性原，满足了神经学领域未被满足的需求，而亚洲市场则为试验提供了投资和患者群体。

Interested parties can schedule meetings by contacting Dr. Doroudian directly. This proactive outreach signals BetterLife's commitment to advancing BETR-001 through collaborative R&D, manufacturing, and market entry strategies tailored for global impact, with Asia as a pivotal hub. Such forums are instrumental in Strategy and Bio Pharma categories, driving executive-level decisions on partnerships and investments..

感兴趣的各方可以通过直接联系 Doroudian 博士来安排会议。这一积极的外联行动表明了 BetterLife 致力于通过协作的研发、制造和针对全球影响的市场进入策略（以亚洲为关键枢纽）来推动 BETR-001 的发展。此类论坛在战略和生物医药领域中具有重要作用，推动高层决策者就合作与投资做出决策。

In the context of 2026's projected M&A momentum and modality innovations like ADCs and radionuclides, BetterLife's LSD-derivative platform represents a unique niche in neuroplastogens, potentially attracting partners seeking novel mechanisms for brain health. The event's timing during JPM Week amplifies visibility among top-tier pharma executives and investors..

在2026年预期的并购势头以及像抗体药物偶联物（ADC）和放射性核素这样的模式创新背景下，BetterLife的LSD衍生品平台在神经塑性因子领域占据了一个独特的细分市场，可能吸引寻求大脑健康新机制的合作伙伴。该活动在摩根大通医疗健康周（JPM Week）期间举行，进一步提升了其在顶级制药企业高管和投资者中的曝光度。

Overall, BetterLife's engagement exemplifies how B2B pharma networking in Asia-centric forums can catalyze progress in Research & Development and Clinical Trials pipelines, ensuring sustainable growth amid evolving regulatory and investment landscapes.

总体而言，BetterLife的参与例证了以亚洲为中心的论坛中B2B制药网络如何推动研发和临床试验管道的进展，确保在不断变化的监管和投资环境中实现可持续增长。